With ties to Georgia Tech, SpherIngenics, Inc. (SPi) had been organizeda round development and commercialization of technologies to enhance the effectiveness of stem cell therapies. SPi had developed a microbead technology enhancing the effectiveness of stem cell based therapies by which “microbeads” can be delivered directly to the treatment site by injection. With a focus on use of the technology for plastic surgery and chronic wound treatment, SpherIngenics (SPi) specializes in the creation and production of patent pending microbeads using alginate, a natural material derived from algae that is commonly used as a food thickener. This process supports product safety but ensures that the cells are precisely localized at the targeted area and maintain continued viability after injection. By staying localized, the encapsulated cell therapies are more effective at replacing damaged tissue. As an added benefit, the microbeads increase the secretion of therapeutic factors, which stimulates the growth and development of the surrounding tissue.
